2019
DOI: 10.3892/ijmm.2019.4414
|View full text |Cite
|
Sign up to set email alerts
|

Combination of the ginsenosides Rb3 and Rb2 exerts protective effects against myocardial ischemia reperfusion injury in rats

Abstract: Ginsenoside Rb3 (G-Rb3) has been demonstrated to alleviate myocardial ischemia reperfusion injury (MIRI); however, it is difficult to separate G-Rb2 from its isomer G-Rb3. The current study aimed to compare the cardioprotective effects of G-Rb3 and the concomitant use of G-Rb3 and G-Rb2 (G-Rb3/Rb2) on MIRI in rats. A rat model of MIRI was established by ligation of the left anterior descending coronary artery and the rats were randomly divided into five groups. Prior to MIRI, G-Rb3/Rb2 (20 mg/kg), G-Rb3 (20 mg… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
24
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 19 publications
(25 citation statements)
references
References 45 publications
1
24
0
Order By: Relevance
“…Diltiazem was purchased from Tianjin Tianyu Pharmaceutical Co., Ltd. (Tianjin, China). Diltiazem (20 mg/kg), a specific L-type calcium channel blocker, was selected as positive control based on previous studies (Zhu et al, 2015;Liu et al, 2020). It has been widely used in the treatment of ischemic heart disease and hypertension (Moukarbel et al, 2004;Liu et al, 2020).…”
Section: Drugsmentioning
confidence: 99%
See 1 more Smart Citation
“…Diltiazem was purchased from Tianjin Tianyu Pharmaceutical Co., Ltd. (Tianjin, China). Diltiazem (20 mg/kg), a specific L-type calcium channel blocker, was selected as positive control based on previous studies (Zhu et al, 2015;Liu et al, 2020). It has been widely used in the treatment of ischemic heart disease and hypertension (Moukarbel et al, 2004;Liu et al, 2020).…”
Section: Drugsmentioning
confidence: 99%
“…Diltiazem (20 mg/kg), a specific L-type calcium channel blocker, was selected as positive control based on previous studies (Zhu et al, 2015;Liu et al, 2020). It has been widely used in the treatment of ischemic heart disease and hypertension (Moukarbel et al, 2004;Liu et al, 2020). Beneficial effects such as infarct size reduction and myocardial performance improvement have been reported following diltiazem treatment (Moukarbel et al, 2004).…”
Section: Drugsmentioning
confidence: 99%
“…Our group is currently undertaking a long-term study assessing the effects of various ginsenosides, including Re, in various animal models of chronic disease, such as hypertension [3,4], CHD [5][6][7], and T2DM. Especially, we had demonstrated that Re improves acute myocardial ischemiamediated myocardial injury, myocardial fibrosis, and heart failure.…”
Section: Introductionmentioning
confidence: 99%
“…Our previous studies has showed that protopanaxadioltype ginsenosides exert significant cardioprotective effects. 6,9,10 In this study, PPD as the active metabolite of protopanaxadioltype ginsenosides significantly attenuated I/R-induced myocardial infarction and improved left ventricular function with decreased LVIDs, LVIDd, and increased EF%, FS%. Elevation of cardiac enzyme, including AST, LDH, and CKMB, indicated the presence of myocardial injury.…”
Section: Discussionmentioning
confidence: 55%
“…6,7 Furthermore, the cardioprotective effects of Rb1, Rb2 and Rb3 were proved by our studies. [8][9][10] But as the active metabolite of these ginsenosides, the effects on myocardial ischemia-reperfusion injury of PPD are still unclear.…”
mentioning
confidence: 99%